Your browser doesn't support javascript.
loading
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori, Koichiro; Suina, Kentaro; Shukuya, Takehito; Takahashi, Fumiyuki; Hayashi, Takuo; Hara, Kieko; Saito, Tsuyoshi; Mitsuishi, Yoichiro; Shimamura, Shoko Sonobe; Winardi, Wira; Tajima, Ken; Ko, Ryo; Mimori, Tomoyasu; Asao, Tetsuhiko; Itoh, Masayoshi; Kawaji, Hideya; Suehara, Yoshiyuki; Takamochi, Kazuya; Suzuki, Kenji; Takahashi, Kazuhisa.
Afiliación
  • Kanamori K; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Suina K; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Shukuya T; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Takahashi F; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Hayashi T; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Hara K; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Saito T; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Mitsuishi Y; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Shimamura SS; Department of Human Pathology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Winardi W; Department of Human Pathology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Tajima K; Department of Human Pathology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Ko R; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Mimori T; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Asao T; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Itoh M; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Kawaji H; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Suehara Y; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Takamochi K; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Suzuki K; Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
  • Takahashi K; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Thorac Cancer ; 14(12): 1089-1097, 2023 04.
Article en En | MEDLINE | ID: mdl-36924358
ABSTRACT

BACKGROUND:

Thymic squamous cell carcinoma and type B3 thymoma are primary neoplasms of the anterior mediastinum that are sometimes difficult to differentiate from one another histologically. However, only a few immunohistochemical markers are available for the differential diagnosis. The purpose of this study was to discover a novel marker for differentiating between thymic squamous cell carcinoma and type B3 thymoma.

METHODS:

We used histological samples of thymic carcinomas (n = 26) and type B3 thymomas (n = 38) which were resected between 1986 and 2017. To search for candidates of differential markers, gene expression levels were evaluated in samples using promoter analysis by cap analysis of gene expression (CAGE) sequencing.

RESULTS:

Promoter level expression of CALML5 genes was significantly higher in thymic carcinomas than in type B3 thymomas. We further validated the results of the CAGE analysis in all 26 thymic carcinomas and 38 type B3 thymomas by immunohistochemistry (IHC). CALML5 was strongly expressed in the cytoplasm in 19 of 26 cases with thymic carcinoma, whereas positivity at the protein level was shown in two of 38 type B3 thymomas. Thus, the sensitivity (73.1%) and specificity (94.7%) of CALML5 as markers for immunohistochemical diagnosis of thymic carcinoma were extremely high.

CONCLUSION:

We identified CALML5 as a potential marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. It is assumed that future clinical use of CALML5 may improve the diagnostic accuracy of differentiating between these two diseases.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Carcinoma de Células Escamosas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Carcinoma de Células Escamosas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Thorac Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón